NetScientific PLC PDS Reports Results for FY2020 & Business Update
RNS Number : 7450S
18 March 2021
("NetScientific", the "Group" or the "Company")
PDS Biotechnology Reports Final Results for the Full Year 2020
& Business Update
London, UK - 18 March 2021 - NetScientific plc (AIM: NSCI), the
life sciences and sustainability technology investment and
commercialisation Group, announces that its portfolio company, PDS
Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced its
financial results for the full year ended 31 December 2020 (the
"Period"), and will be hosting a conference call to review the
results and provide a business update.
PDS Highlights for the Period:
-- Achieved preliminary efficacy benchmark in the Phase 2
combination trial of PDS0101 led by the National Cancer
-- Initiated VERSATILE-002, a Phase 2 trial of lead
investigational drug candidate PDS0101, in combination with
standard of care KEYTRUDA(R) for first-line treatment of patients
with metastatic or recurrent HPV-positive head and neck cancer.
-- Phase 2 trial of lead investigational drug candidate PDS0101,
in combination with standard of care chemoradiotherapy for patients
with advanced cervical cancer was initiated by the University of
Texas MD Anderson Cancer Center.
-- Expanded consortium for development of PDS0203, a novel,
Versamune(R) -based second-generation COVID-19 vaccine to include
Blanver Farmoquímica in addition to Farmacore.
-- Received award commitment of up to $60 million from Brazil's
Ministry of Science, Technology and Innovation (MCTI) to fund
clinical development and commercialization of PDS0203.
-- Strengthened leadership team with the appointment of Seth Van
Voorhees as Chief Financial Officer and addition of preeminent
oncologist Otis Brawley, M.D. to the board of directors.
PDS will be hosting a conference call today to discuss the
results. For further details and to register please follow the link
to their full announcement below.
Dr. Ilian Iliev, CEO of NetScientific and Director of PDS
Biotechnology commented: "As a long-term investor in PDS
Biotechnology, we are delighted with the company's breakthrough
performance in 2020, despite the operational challenges of the
COVID-19 pandemic. The company's continued R&D investment and
engagement with industry have resulted in significant progress in
its cancer immunotherapy and COVID vaccine programmes. PDS is a
good example of NetScientific's investment philosophy in practice,
where we provide pro-active and judicious investment to support the
execution of our portfolio companies' ambitious plans."
NetScientific holds approximately 5.75% of PDS' undiluted share
The full text of the announcement from PDS Biotechnology can be
found here: PDS Biotech - PDS Biotech Reports Financial Results for
the Year Ended December 31, 2020 and Provides Business Update
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Anna Dunphy/ Nick Rome/ Paul McManus/ 07876 741 001 or 07748 325 236
Nicholas Johnson or 07980 541 893
or 07884 664 686
NetScientific Plc is a life sciences and sustainability
technology investment and commercialisation Group, leveraging
trans-Atlantic relationships and global opportunities to deliver
For more information, please visit the website at
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact firstname.lastname@example.org or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
March 18, 2021 07:48 ET (11:48 GMT)